Biotechnology
Compare Stocks
2 / 10Stock Comparison
CGEN vs NKTX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
CGEN vs NKTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $256M | $223M |
| Revenue (TTM) | $5M | $0.00 |
| Net Income (TTM) | $-31M | $-103M |
| Gross Margin | -5.2% | — |
| Operating Margin | -6.5% | — |
| Total Debt | $3M | $80M |
| Cash & Equiv. | $18M | $28M |
CGEN vs NKTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 20 | May 26 | Return |
|---|---|---|---|
| Compugen Ltd. (CGEN) | 100 | 19.8 | -80.2% |
| Nkarta, Inc. (NKTX) | 100 | 12.2 | -87.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CGEN vs NKTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CGEN is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.68
- -57.2% 10Y total return vs NKTX's -93.4%
- Lower volatility, beta 1.68, Low D/E 5.3%, current ratio 5.26x
NKTX carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 33.3%
- 8.0% revenue growth vs CGEN's -16.7%
- 3.9% margin vs CGEN's -5.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.0% revenue growth vs CGEN's -16.7% | |
| Quality / Margins | 3.9% margin vs CGEN's -5.8% | |
| Stability / Safety | Beta 1.68 vs NKTX's 2.07, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +128.8% vs NKTX's +68.4% | |
| Efficiency (ROA) | -24.0% ROA vs CGEN's -32.0%, ROIC -24.3% vs -24.1% |
CGEN vs NKTX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
CGEN and NKTX operate at a comparable scale, with $5M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $5M | $0 |
| EBITDAEarnings before interest/tax | -$33M | -$113M |
| Net IncomeAfter-tax profit | -$31M | -$103M |
| Free Cash FlowCash after capex | $0 | -$94M |
| Gross MarginGross profit ÷ Revenue | -5.2% | — |
| Operating MarginEBIT ÷ Revenue | -6.5% | — |
| Net MarginNet income ÷ Revenue | -5.8% | — |
| FCF MarginFCF ÷ Revenue | +177.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +25.6% |
Valuation Metrics
Evenly matched — CGEN and NKTX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $256M | $223M |
| Enterprise ValueMkt cap + debt − cash | $241M | $275M |
| Trailing P/EPrice ÷ TTM EPS | -17.88x | -1.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.19x | — |
| Price / BookPrice ÷ Book value/share | 4.66x | 0.52x |
| Price / FCFMarket cap ÷ FCF | 5.17x | — |
Profitability & Efficiency
CGEN leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
NKTX delivers a -30.4% return on equity — every $100 of shareholder capital generates $-30 in annual profit, vs $-72 for CGEN. CGEN carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to NKTX's 0.20x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -71.5% | -30.4% |
| ROA (TTM)Return on assets | -32.0% | -24.0% |
| ROICReturn on invested capital | -24.1% | -24.3% |
| ROCEReturn on capital employed | -15.7% | -30.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.05x | 0.20x |
| Net DebtTotal debt minus cash | -$15M | $52M |
| Cash & Equiv.Liquid assets | $18M | $28M |
| Total DebtShort + long-term debt | $3M | $80M |
| Interest CoverageEBIT ÷ Interest expense | -437.97x | — |
Total Returns (Dividends Reinvested)
CGEN leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CGEN five years ago would be worth $3,771 today (with dividends reinvested), compared to $1,139 for NKTX. Over the past 12 months, CGEN leads with a +128.8% total return vs NKTX's +68.4%. The 3-year compound annual growth rate (CAGR) favors CGEN at 62.6% vs NKTX's -11.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +84.5% | +68.4% |
| 1-Year ReturnPast 12 months | +128.8% | +68.4% |
| 3-Year ReturnCumulative with dividends | +330.1% | -31.5% |
| 5-Year ReturnCumulative with dividends | -62.3% | -88.6% |
| 10-Year ReturnCumulative with dividends | -57.2% | -93.4% |
| CAGR (3Y)Annualised 3-year return | +62.6% | -11.9% |
Risk & Volatility
CGEN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CGEN is the less volatile stock with a 1.68 beta — it tends to amplify market swings less than NKTX's 2.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 2.07x |
| 52-Week HighHighest price in past year | $3.23 | $3.65 |
| 52-Week LowLowest price in past year | $1.23 | $1.63 |
| % of 52W HighCurrent price vs 52-week peak | +88.4% | +86.3% |
| RSI (14)Momentum oscillator 0–100 | 56.4 | 66.9 |
| Avg Volume (50D)Average daily shares traded | 431K | 802K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CGEN as "Buy" and NKTX as "Buy". Consensus price targets imply 585.7% upside for NKTX (target: $22) vs 39.9% for CGEN (target: $4).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $21.60 |
| # AnalystsCovering analysts | 13 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
CGEN leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 1 category is tied.
CGEN vs NKTX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CGEN or NKTX a better buy right now?
Analysts rate Compugen Ltd.
(CGEN) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CGEN or NKTX?
Over the past 5 years, Compugen Ltd.
(CGEN) delivered a total return of -62. 3%, compared to -88. 6% for Nkarta, Inc. (NKTX). Over 10 years, the gap is even starker: CGEN returned -57. 2% versus NKTX's -93. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CGEN or NKTX?
By beta (market sensitivity over 5 years), Compugen Ltd.
(CGEN) is the lower-risk stock at 1. 68β versus Nkarta, Inc. 's 2. 07β — meaning NKTX is approximately 23% more volatile than CGEN relative to the S&P 500. On balance sheet safety, Compugen Ltd. (CGEN) carries a lower debt/equity ratio of 5% versus 20% for Nkarta, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CGEN or NKTX?
On earnings-per-share growth, the picture is similar: Nkarta, Inc.
grew EPS 33. 3% year-over-year, compared to 23. 8% for Compugen Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CGEN or NKTX?
Nkarta, Inc.
(NKTX) is the more profitable company, earning 0. 0% net margin versus -51. 1% for Compugen Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTX leads at 0. 0% versus -53. 4% for CGEN. At the gross margin level — before operating expenses — CGEN leads at 71. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CGEN or NKTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CGEN or NKTX better for a retirement portfolio?
For long-horizon retirement investors, Compugen Ltd.
(CGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Nkarta, Inc. (NKTX) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CGEN: -57. 2%, NKTX: -93. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CGEN and NKTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.